Sponsored
Success in emerging biopharma depends not only on speed, but also on making confident, data-informed decisions early in development while managing increasing molecular complexity.
Laura Daley, PhD, Catalent Pharma Solutions
Advertisement
Articles by Laura Daley, PhD, Catalent Pharma Solutions
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
2
FDA Rare Disease Framework Initiative: What It Means for Drug and Biologic Development
3
Alvotech, Advanz Submit First Eylea 8 mg Biosimilar Bid
4
FDA Expands Anktiva Approval to Papillary-Only BCG-Unresponsive Bladder Cancer
5